{"disease":{"id":"glomerulosclerosis-focal-segmental","name":"glomerulosclerosis focal segmental"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00001393","title":"Genetic Markers for Focal Segmental Glomerulosclerosis","phase":"","overall_status":"COMPLETED","enrollment_count":616,"lead_sponsor_name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","has_results":false},{"nct_id":"NCT03949972","title":"The FOrMe Registry (The German Focal Segmental Glomerulosclerosis and Minimal Change Disease Registry)","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Prof. Dr. Paul Brinkkoetter","has_results":false},{"nct_id":"NCT05505500","title":"Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.","phase":"","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"University of Michigan","has_results":false},{"nct_id":"NCT04387448","title":"A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":96,"lead_sponsor_name":"Goldfinch Bio, Inc.","has_results":false},{"nct_id":"NCT04950114","title":"An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":31,"lead_sponsor_name":"Goldfinch Bio, Inc.","has_results":false},{"nct_id":"NCT04235621","title":"A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN)","phase":"","overall_status":"TERMINATED","enrollment_count":20,"lead_sponsor_name":"Goldfinch Bio, Inc.","has_results":false},{"nct_id":"NCT02000440","title":"A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT04340362","title":"Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"Vertex Pharmaceuticals Incorporated","has_results":true},{"nct_id":"NCT00098020","title":"Podocyte Retinoids","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","has_results":true}],"total":9},"guidelines":[],"source":"Drug Landscape verified database"}